Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ Allergy Study
PLRZ has more than doubled off its 52-week low of $2.88 on elevated volume (4.8× avg).
Summary
Polyrizon has finalized contracts with all five U.S. clinical sites for its NASARIX™ Allergy Blocker first-in-human study, moving from three sites reported in June to full site activation. This operational milestone clears the way for patient pre-screening and enrollment, which will be timed to seasonal allergen exposure. The study will enroll up to 120 patients with seasonal allergic rhinitis, with primary efficacy measured by Total Nasal Symptom Score over 14 days. For a development-stage biotech with a market cap around $30 million, completing site contracting is a meaningful de-risking step toward clinical data. The next key event will be initiation of patient enrollment, expected to align with allergy season.
At the time of this announcement, PLRZ was trading at $14.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.9M. The 52-week trading range was $2.88 to $18.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.